CADTH reimbursement recommendation: Infliximab SC (Remsima SC) indication: rheumatoid arthritis : recommendation : reimburse with conditions
Clinical evidence suggests that Remsima (infliximab) SCshould be reimbursed to treat adults with moderately to severely active RA in a similar way to other infliximab products, only if the cost does not exceed the drug plan cost of the least expensive IV formulation of infliximab
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, April 2021
|
| Edition: | Version: 1.0 |
| Series: | CADTH reimbursement review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Clinical evidence suggests that Remsima (infliximab) SCshould be reimbursed to treat adults with moderately to severely active RA in a similar way to other infliximab products, only if the cost does not exceed the drug plan cost of the least expensive IV formulation of infliximab |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (8 pages) |